Clinical Trials Browser

Neoplasm, Residual × obinutuzumab × Clear all

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT02666898 2025-11-26

ICLL07GAI

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell